RZG - ETF AI Analysis
Top Page
Invesco S&P Smallcap 600 Pure Growth ETF (RZG)
Rating:71Outperform
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has delivered strong gains so far this year, showing solid momentum in its small-cap growth strategy.
Top Holdings Showing Strong Growth
Many of the largest positions, such as ACM Research, Powell Industries, and Liquidia Technologies, have posted strong year-to-date performance, helping drive the fund’s returns.
Broad Sector Diversification
Holdings spread across health care, technology, financials, industrials, and several other sectors help reduce the impact if any one industry runs into trouble.
Negative Factors
Higher Expense Ratio for a Passive ETF
The fund’s expense ratio is on the higher side for an index-based ETF, which means more of your returns go toward fees over time.
Concentration in U.S. Market Only
With essentially all assets invested in U.S. companies, the ETF offers no geographic diversification and is fully exposed to the U.S. economic cycle.
Heavy Tilt Toward Small-Cap Growth
Because the fund focuses on smaller, fast-growing companies, its share price can be more volatile and sensitive to changes in investor sentiment than broader market funds.
RZG vs. SPDR S&P 500 ETF (SPY)
AUM138.88M
RegionNorth America
Expense Ratio0.35%
Beta0.97
IssuerInvesco
Inception DateMar 01, 2006
Dividend Yield0.44%
Asset ClassEquity
Index TrackedS&P Small Cap 600 Pure Growth
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume11,396
30 Day Avg. Volume15,055
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
85.17Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering127
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
RZG Summary
The Invesco S&P SmallCap 600 Pure Growth ETF (RZG) follows the S&P SmallCap 600 Pure Growth Index, focusing on fast-growing smaller U.S. companies. It holds a mix of health care, technology, financial, and industrial stocks, including names like ACM Research and Clear Secure. Someone might invest in RZG to seek higher growth by backing smaller, more agile businesses and to diversify beyond large, well-known companies. However, because it focuses on small growth stocks, its price can be more volatile and can go up and down sharply with changes in the market.
How much will it cost me?The Invesco S&P SmallCap 600 Pure Growth ETF (RZG) has an expense ratio of 0.35%, which means you’ll pay $3.50 per year for every $1,000 invested. This is slightly higher than average because it is designed to track a specific niche index of small-cap growth companies, requiring more active management. It’s a good option if you’re looking for targeted exposure to high-growth small-cap stocks.
What would affect this ETF?The ETF's focus on U.S. small-cap growth companies means it could benefit from economic expansion, increased innovation, and favorable conditions for entrepreneurial businesses, particularly in sectors like health care and technology. However, it may face challenges from rising interest rates, which can increase borrowing costs for smaller companies, or economic slowdowns that disproportionately impact small-cap stocks. Regulatory changes in key sectors like health care or financials could also influence performance.
RZG Top 10 Holdings
RZG is powered by a pack of fast-moving U.S. small-cap growth names, with health care and tech leading the charge. Liquidia Technologies has been a standout, rising strongly on momentum and product news, while Dave and Protagonist Therapeutics add steady fuel to the fund’s growth engine. On the flip side, ACM Research and Powell Industries have been lagging lately, acting as a bit of a brake on performance despite solid longer-term stories. Overall, the ETF leans into innovative, domestically focused small caps rather than global giants.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ACM Research | 2.35% | $3.25M | $5.79B | 231.98% | 72 Outperform | |
| Protagonist Therapeutics | 1.92% | $2.66M | $9.44B | 179.07% | 68 Neutral | |
| Acadian Asset Management | 1.74% | $2.40M | $3.19B | 100.09% | 66 Neutral | |
| Karman Holdings Inc. | 1.73% | $2.39M | $7.72B | 33.10% | 62 Neutral | |
| Liquidia Technologies | 1.70% | $2.35M | $8.02B | 329.39% | 57 Neutral | |
| DXP Enterprises | 1.59% | $2.19M | $2.98B | 66.89% | 71 Outperform | |
| Enova International | 1.53% | $2.11M | $6.29B | 142.21% | 71 Outperform | |
| The Chefs' Warehouse | 1.52% | $2.10M | $4.50B | 74.69% | 72 Outperform | |
| Dave | 1.52% | $2.10M | $4.06B | 65.39% | 80 Outperform | |
| Life360, Inc. | 1.49% | $2.06M | $5.12B | -12.38% | 66 Neutral |
RZG Technical Analysis
Positive
―
Price Trends
68.99
Positive
65.26
Positive
60.64
Positive
Market Momentum
0.21
Positive
50.09
Neutral
48.69
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For RZG, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 69.54, equal to the 50-day MA of 68.99, and equal to the 200-day MA of 60.64, indicating a bullish trend. The MACD of 0.21 indicates Positive momentum. The RSI at 50.09 is Neutral, neither overbought nor oversold. The STOCH value of 48.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RZG.
RZG Peer Comparison
Comparison Results
Performance Comparison
RZG
Invesco S&P Smallcap 600 Pure Growth ETF
69.93
16.53
30.96%
OUSM
OShares U.S. Small-Cap Quality Dividend ETF
―
―
―
JHSC
John Hancock Multifactor Small Cap ETF
―
―
―
EES
WisdomTree U.S. SmallCap Fund
―
―
―
BBSC
JPMorgan BetaBuilders U.S. Small Cap Equity ETF
―
―
―
JSML
Janus Henderson Small Cap Growth Alpha ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents